Literature DB >> 23206831

Preoperative serum CYFRA 21-1 level as a prognostic factor in surgically treated adenocarcinoma of lung.

Seong Yong Park1, Jin Gu Lee, Jieun Kim, Yongjung Park, Seok Kee Lee, Mi Kyung Bae, Chang Young Lee, Dae Joon Kim, Kyung Young Chung.   

Abstract

BACKGROUND: High preoperative serum CYFRA 21-1 has been reported as diagnostic marker and poor prognostic factor in non-small cell lung cancer, especially in squamous cell carcinoma. However, the prognostic value in adenocarcinoma of lung has not been reported. This study is performed to investigate the prognostic impact of CYFRA 21-1 in adenocarcinoma of lung.
METHODS: We retrospectively reviewed 298 patients who underwent lobectomy or above with complete mediastinal lymph node dissection for adenocarcinoma of lung, between 2004 and 2009. The patients were divided into 2 groups, by receiver operating characteristic (ROC) curve analysis.
RESULTS: There were 145 male patients and mean age was 62.2 ± 26.4 years. The median follow-up period was 43.3 months. Mean and median value of CYFRA 21-1 were 2.16 ± 1.97 ng/mL and 1.68 ng/mL (range, 0.37-15.10), respectively. The optimal cut-off value of CYFRA 21-1 for overall survival was 1.95 ng/mL which was determined by ROC curve analysis. One hundred fourteen (38.4%) patients showed high level of CYFRA 21-1. Preoperative serum CYFRA 21-1 was higher in advanced stage (p=0.004). The high CYFRA 21-1 was also correlated with bigger tumor size (p<0.001) and poor differentiation (p=0.008). The 5-year overall survival of low group and high group was 79.1% and 58.4% (p<0.001), respectively. Univariate and multivariate analysis showed that CYFRA 21-1 level was related to the poor prognosis for overall survival (hazard ratio=1.1, p=0.033) in adenocarcinoma of lung. The concordance index for Cox model was also higher in multivariate analysis model with CYFRA 21-1 level than in model without CYFRA 21-1 level (0.722, 95% CI 0.718-0.726 vs. 0.701, 95% CI 0.697-0.705).
CONCLUSIONS: High preoperative CYFRA 21-1 may be a determinant for poor prognosis in operated adenocarcinoma of lung.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23206831     DOI: 10.1016/j.lungcan.2012.11.006

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  20 in total

1.  Prognostic impact of cytological fluid tumor markers in non-small cell lung cancer.

Authors:  Arthur Cho; Jin Hur; Yoo Jin Hong; Hye-Jeong Lee; Young Jin Kim; Sae Rom Hong; Young Joo Suh; Dong Jin Im; Yun Jung Kim; Jae Seok Lee; Hyo Sup Shim; Byoung Wook Choi
Journal:  Tumour Biol       Date:  2015-10-02

Review 2.  History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer.

Authors:  Haruhiko Nakamura; Toshihide Nishimura
Journal:  Surg Today       Date:  2017-02-22       Impact factor: 2.549

3.  Toward rapid, high-sensitivity, volume-constrained biomarker quantification and validation using backscattering interferometry.

Authors:  Ian R Olmsted; Mohamed Hassanein; Amanda Kussrow; Megan Hoeksema; Ming Li; Pierre P Massion; Darryl J Bornhop
Journal:  Anal Chem       Date:  2014-07-07       Impact factor: 6.986

4.  Increases in serum CYFRA21-1 concentration during successful treatment with crizotinib.

Authors:  Nobuhiro Kanaji; Akira Tadokoro; Naoki Watanabe; Takuya Inoue; Tomoya Ishii; Hiroaki Dobashi; Shuji Bandoh
Journal:  Am J Case Rep       Date:  2014-11-03

5.  CYFRA 21-1 is an early predictor of chemotherapeutic effectiveness in advanced nonsmall cell lung cancer: An observational study.

Authors:  Tongwei Zhao; Ying Jin; Guangyun Mao; Yaping Wei; Guoqing Wu; Xiao Ye; Yonglie Zhou; Guorong Yuan; Liang Gao; Yupeng Hong; Yun Chen; Chaojin Hong; Hongying Zhou; Dan Su; Zhiquan Qin; Liqin Lu
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

6.  The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients.

Authors:  Li Zhang; Dan Liu; Lei Li; Dan Pu; Ping Zhou; Yuting Jing; He Yu; Yanwen Wang; Yihan Zhu; Yanqi He; Yalun Li; Shuang Zhao; Zhixin Qiu; Weimin Li
Journal:  BMC Cancer       Date:  2017-02-02       Impact factor: 4.430

7.  Development and validation of a preoperative prognostic index independent of TNM stage in resected non-small cell lung cancer.

Authors:  Shogo Kumagai; Satoshi Marumo; Machiko Arita; Keiji Yamanashi; Ryota Sumitomo; Yosuke Otake; Tsuyoshi Shoji; Motonari Fukui; Toshiro Katayama; Norihito Okumura; Cheng-Long Huang
Journal:  BMC Pulm Med       Date:  2017-12-04       Impact factor: 3.317

8.  Assessment of relationships among clinicopathological characteristics, morphological computer tomography features, and tumor cell proliferation in stage I lung adenocarcinoma.

Authors:  Xiaoling Ma; Shuchang Zhou; Lu Huang; Peijun Zhao; Yujin Wang; Qiongjie Hu; Liming Xia
Journal:  J Thorac Dis       Date:  2021-05       Impact factor: 2.895

9.  Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study.

Authors:  Akira Ono; Toshiaki Takahashi; Keita Mori; Hiroaki Akamatsu; Takehito Shukuya; Tetsuhiko Taira; Hirotsugu Kenmotsu; Tateaki Naito; Haruyasu Murakami; Takashi Nakajima; Masahiro Endo; Nobuyuki Yamamoto
Journal:  BMC Cancer       Date:  2013-07-23       Impact factor: 4.430

10.  Prognostic value of serum leptin in advanced lung adenocarcinoma patients with cisplatin/pemetrexed chemotherapy.

Authors:  Wenjun Mou; Hui Xue; Hongli Tong; Shengjie Sun; Zhuhong Zhang; Chunyan Zhang; Qiyu Sun; Jing Dong; Xinyu Wen; Guangtao Yan; Yaping Tian
Journal:  Oncol Lett       Date:  2014-03-21       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.